Jixing Pharmaceuticals Enrolls First Patient in Etripamil Phase III Study for PSVT
China-based Ji Xing Pharmaceuticals Ltd (Jixing) announced the first patient enrollment in a Phase III...
Takeda’s Obizur Prioritized for Review in Acquired Hemophilia A Treatment
The Center for Drug Evaluation (CDE) website indicates that Takeda Pharmaceutical Co., Ltd’s Obizur (susoctocog...
Corestar Biotech Secures Series A Funding for POCT R&D Expansion
Shenzhen-based point-of-care testing (POCT) specialist Corestar Biotechnology Co., Ltd has raised “tens of millions” of...
Great Robotics Raises RMB 100M for Surgical Robot Development
Great Robotics, a Beijing-based medical robotics company, has reportedly raised close to RMB 100 million...
Visum Pharma Series B+ Financing to Advance R&D and GMP Workshop Construction
Visum Pharmaceutical Co., Ltd reportedly raised close to RMB 100 million (USD 14.9 million) in...
Yunnan Jianzhijia Plans Acquisition of Hebei Tangren Pharmacy in USD 309 Million Deal
China-based Yunnan Jianzhijia Health-Chain Co, Ltd (SHA: 605266) plans to acquire 100% of compatriot firm...
Sun Pharma Loses VBP Bid for Bicalutamide in China Due to Quality Failures
The Shanghai Medical Products Administration (SMPA) has revoked the winning bid of India-based Sun Pharmaceutical...
Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for First-Line NSCLC Treatment
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that it has received another indication approval from...
Dakang Medical Secures RMB 400M in Series E Round for Hemodialysis Center Expansion
Dakang Medical (DiaCare Medical), a Beijing-based provider of blood purification chain medical services, has reportedly...
Ascentage Pharma’s APG-5918 Receives FDA Approval for First-in-Human Study
Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from the US Food...
Luzhu Bio Files for Hong Kong IPO After RMB 4.42 Billion Valuation
Beijing Luzhu Biotechnology Co., Ltd, a leading developer of human vaccines and therapeutic biologics, has...
Youwe Bio’s Series B Financing to Advance Microneedle Technology Commercialization
China-based Youwe (Zhuhai) Biotechnology Co., Ltd, a developer of soluble microneedle transdermal drug delivery technology,...
NHSA Updates NRDL with Focus on Expert Review and Simplified Renewals
The National Healthcare Security Administration (NHSA) has released the “2022 National Reimbursement Drug List (NRDL)...
Ascletis Pharma Doses First Patient in China’s Phase II Trial for HIV-1 Treatment with ASC22
China-based Ascletis Pharma Inc. (HKG: 1672) announced the dosing of the first patient in its...
Jixing Pharmaceuticals’ Aficamten Receives CDE Approval for Phase III HCM Study
China-based Ji Xing Pharmaceuticals announced receiving approval from the Center for Drug Evaluation (CDE) to...
BDgene Advances CRISPR-Based BD111 for Herpes Keratitis with IND Filing
Shanghai BDgene Technology Co., Ltd has completed efficacy and preliminary safety studies for BD111, its...
MicroPort NeuroTech Lists in Hong Kong with $43.3 Million IPO
MicroPort NeuroTech Limited has successfully completed its initial public offering (IPO) on the Hong Kong...
Bayer’s Kerendia Approved by China’s NMPA for Diabetic Kidney Disease
The National Medical Products Administration (NMPA) has approved Bayer’s (ETR: BAYN) Category 1 drug Kerendia...
Hengrui Medicine’s SHR3680 Approved for High Burden Metastatic Prostate Cancer
China’s Hengrui Medicine Co., Ltd. (SHA: 600276) announced that its Category 1 drug SHR3680 has...
Legend Biotech Collaborates with Trinity College Dublin on CAR-T Therapies for Solid Tumors
China-based Legend Biotech Corporation (NASDAQ: LEGN) has formed a partnership with Trinity College Dublin and...